STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Amendment: Janus Henderson Reports 4.57M ADS (8.0%) in GPCR

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Janus Henderson Group plc filed Amendment No. 3 to a Schedule 13G reporting ownership in Structure Therapeutics Inc. The filing lists 4,573,006 American Depositary Shares, representing 8.0% of the class, with shared voting and dispositive power. A subsidiary disclosure shows JHIUS may be deemed beneficial owner of 4,449,167 shares (7.7%) with shared voting and dispositive power. The report cites the event date 06/30/2025 and is signed on 08/14/2025 by Kristin Mariani. The filer certifies the position is held in the ordinary course and not to influence control. A power of attorney executed on 12/09/2022 is attached.

Positive

  • Material disclosure: Janus Henderson reports 4,573,006 ADS (8.0%), exceeding the 5% reporting threshold
  • Transparency: Filing includes certification that shares are held in the ordinary course and not to influence control
  • Documentation: Power of attorney and signature by the Head of North America Compliance are included

Negative

  • Figure discrepancy: The filing shows 4,573,006 ADS (8.0%) aggregate while also reporting 4,449,167 shares (7.7%) for JHIUS, which may cause confusion without further detail
  • No sole voting power: The filer reports 0 shares of sole voting power, indicating no direct controlling stake

Insights

TL;DR: Janus Henderson reports a material passive stake—4,573,006 ADS (8.0%)—in Structure Therapeutics, disclosed via Schedule 13G Amendment No.3.

The filing explicitly reports an aggregate beneficial position of 4,573,006 ADS (8.0%) with shared voting and dispositive power, indicating a sizable institutional holding above the 5% reporting threshold. The filing is submitted under Rule 13d-1(b) and includes the certification that the securities are held in the ordinary course and not to influence control. The Schedule also identifies a related subsidiary position of 4,449,167 shares (7.7%), and provides a power of attorney for filing authority.

TL;DR: Disclosure shows a significant passive position but contains differing subsidiary and aggregate share figures that merit careful reading.

The document classifies the stake as passive per Schedule 13G and includes the required certification. It reports shared voting/dispositive power rather than sole control, and attaches a power of attorney dated December 9, 2022. Notably, the filing presents two similar but different figures—4,573,006 ADS (8.0%) aggregate and 4,449,167 shares (7.7%) for JHIUS—which are both stated in the filing and should be interpreted as distinct disclosures included by the reporting group.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



JANUS HENDERSON GROUP PLC
Signature:Kristin Mariani
Name/Title:Head of North America Compliance, CCO
Date:08/14/2025
Exhibit Information

POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

FAQ

How many Structure Therapeutics (GPCR) shares does Janus Henderson own?

The filing reports an aggregate beneficial position of 4,573,006 ADS (8.0%). A related subsidiary (JHIUS) is reported as beneficial owner of 4,449,167 shares (7.7%).

What type of SEC filing did Janus Henderson submit for GPCR?

Janus Henderson filed an Amendment No. 3 to Schedule 13G under Rule 13d-1(b).

When is the event date and when was the Schedule 13G signed?

The date of the event requiring the filing is 06/30/2025, and the filing is signed on 08/14/2025.

Does the filing indicate intent to influence control of Structure Therapeutics (GPCR)?

The filer certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

Who signed the Schedule 13G for Janus Henderson?

The filing is signed by Kristin Mariani, Head of North America Compliance, CCO.

Is there a power of attorney attached to the filing?

Yes. A power of attorney dated 12/09/2022 names Kristin Mariani and Caroline Barotti to execute ownership reporting filings.
Structure Therapeutics Inc ADR

NASDAQ:GPCR

GPCR Rankings

GPCR Latest News

GPCR Latest SEC Filings

GPCR Stock Data

2.08B
57.80M
3.04%
98.22%
12.05%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO